Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bipolar Androgen Therapy Followed by Darolutamide vs. Standard of Care in mCRPC
NCT07852195Phase 3Not yet recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jan 2027
- Primary completion
- Mar 2029
01
Overview
Phase 3, randomised, open-label trial of testosterone cypionate and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoints: Second progression-free survival up to 60 months, Overall survival up to 60 months and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
testosterone cypionatedarolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07852195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852195.